Regulus Therapeutics (RGLS) to Release Quarterly Earnings on Thursday

Regulus Therapeutics (NASDAQ:RGLS) is anticipated to issue its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter.

Regulus Therapeutics Trading Up 11.3 %

Shares of NASDAQ RGLS opened at $1.48 on Thursday. The firm has a 50 day moving average of $1.29 and a 200 day moving average of $1.47. The firm has a market capitalization of $96.94 million, a price-to-earnings ratio of -1.38 and a beta of 1.41. Regulus Therapeutics has a 12-month low of $0.83 and a 12-month high of $3.00.

Insiders Place Their Bets

In other news, CEO Joseph P. Hagan purchased 50,000 shares of the company’s stock in a transaction on Thursday, January 30th. The stock was acquired at an average cost of $1.09 per share, for a total transaction of $54,500.00. Following the completion of the transaction, the chief executive officer now directly owns 260,808 shares in the company, valued at $284,280.72. This trade represents a 23.72 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Crispina Calsada sold 38,716 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $1.26, for a total transaction of $48,782.16. Following the completion of the transaction, the chief financial officer now owns 50,566 shares of the company’s stock, valued at approximately $63,713.16. The trade was a 43.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 223,998 shares of company stock worth $282,237 over the last three months. 4.35% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Regulus Therapeutics in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Regulus Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $10.80.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.